Fundraising FoxMenlo Therapeutics
Menlo Park, US · Delaware corporation · 10 known investors
Find your way into Menlo Therapeutics
Sign up to see every warm intro you have to Menlo Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Menlo Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
SL
Steven L. BastaExecutive
JC
John CreecyNamed on SEC filing
SW
Scott WhitcupNamed on SEC filing
TE
Ted EbelNamed on SEC filing
KP
Ketan PatelNamed on SEC filing
DC
David CollierNamed on SEC filing
Board
AC
Albert ChaBoard director
AR
Investors · 10
Aisling CapitalreportedNew York
How we know: prnewswire.com · Not right? Tell us
Also in the syndicate · 3
Presidio PartnersRemeditexvenBiolead
Reported raises · per SEC filings
Form D private placements$139M disclosed across 3 rounds · 2017–2023
▶$88.2MraisedNov 2023 · 19 investors · BiotechnologyRule 506(b)
▶$88.2MraisedNov 2023 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- SHARON BARBARIDirector
- MUTYA HARSCHExecutive Officer
- TYLER ZERONDAExecutive Officer
- DAVID DOMZALSKIExecutive Officer, Director
- ELISABETH SANDOVALDirector
- PATRICK LEPOREDirector
- STEVEN BASTADirector
- IAIN STUARTExecutive Officer
- ANTHONY BRUNODirector
- Offering amount
- $88.2M
- Amount sold
- $88.2M
- Sales commissions
- $5M
- Placement agents
- LifeSci Capital LLC
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$300KraisedNov 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$300KraisedNov 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- ANTHONY BRUNODirector
- PATRICK LEPOREDirector
- IAIN STUARTExecutive Officer
- STEVEN BASTADirector
- ELISABETH SANDOVALDirector
- DAVID DOMZALSKIExecutive Officer, Director
- TYLER ZERONDAExecutive Officer
- MUTYA HARSCHExecutive Officer
- SHARON BARBARIDirector
- Offering amount
- $300K
- Amount sold
- $300K
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50.5MraisedJul 2017 · 11 investors · PharmaceuticalsRule 506(b)
▶$50.5MraisedJul 2017 · 11 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Albert ChaDirector
- Steven L. BastaExecutive Officer, Director
- John CreecyDirector
- Scott WhitcupDirector
- Aaron RoystonDirector
- Ted EbelDirector
- Ketan PatelDirector
- David CollierDirector
- Offering amount
- $50.5M
- Amount sold
- $50.5M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Menlo Therapeutics's investors?
- Menlo Therapeutics's investors include Aisling Capital, Bay City Capital, F-Prime Capital, Novo Holdings, Rock Springs Capital, venBio Partners, Vivo Capital.
- How much funding has Menlo Therapeutics raised?
- Menlo Therapeutics has disclosed $139M raised across 3 rounds.
- Where is Menlo Therapeutics headquartered?
- Menlo Therapeutics is headquartered in Menlo Park, US.